GSK - GlaxoSmithKline plc
39.99 +0.06 (0.15%)
After hours: 4:29PM EDT
| Previous Close | 40.22 |
| Open | 40.14 |
| Bid | 39.93 x 1000 |
| Ask | 40.46 x 3200 |
| Day's Range | 39.81 - 40.19 |
| 52 Week Range | 36.41 - 42.36 |
| Volume | 2,744,226 |
| Avg. Volume | 2,675,667 |
| Market Cap | 98.443B |
| Beta (3Y Monthly) | 0.54 |
| PE Ratio (TTM) | 40.25 |
| EPS (TTM) | 0.99 |
| Earnings Date | Feb 1, 2017 - Feb 6, 2017 |
| Forward Dividend & Yield | 2.39 (5.71%) |
| Ex-Dividend Date | 2019-02-21 |
| 1y Target Est | 44.33 |
- Zacks•4 hours ago
Lannett (LCI) to Report Q3 Earnings: What's in the Cards?
Lannet (LCI) will release fiscal third-quarter earnings and is expected to provide an update on product launches
- Associated Press•7 hours ago
Drug maker to spend $100M expanding Montana facility
HAMILTON, Mont. (AP) — Drugmaker GlaxoSmithKline has announced $100 million of new investment in its manufacturing site in Montana.
- Zacks•11 hours ago
Novartis (NVS) Q1 Earnings Beat Estimates, Revenues Up Y/Y
Novartis (NVS) beats on Q1 earnings, sales marginally miss estimates.
- Financial Times•17 hours ago
Malawi starts pilot of malaria vaccine for children
A large-scale pilot of a vaccine that could prevent some of the 250,000 child deaths each year from malaria has begun in Malawi after successful clinical trials. The vaccine — called RTS,S — acts against the most deadly malaria parasite and has been in development by GlaxoSmithKline for more than three decades. According to the World Health Organization, it is the first vaccine to demonstrate it can significantly reduce cases of malaria in children.
- Zacks•yesterday
Alexion (ALXN) to Report Q1 Earnings: What's in the Cards?
Alexion's (ALXN) first-quarter 2019 results are likely to gain on solid performance of lead drug, Soliris. Investors will also focus on updates on pipeline candidates.
- Zacks•yesterday
What's in Store for Celgene Corporation (CELG) Q1 Earnings?
Investors are looking forward to Revlimid's performance and updates on the impending acquisition agreement with Bristol-Myers, when Celgene Corporation (CELG) reports Q1 results.
- Zacks•yesterday
Are Investors Undervaluing GlaxoSmithKline (GSK) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- Motley Fool•yesterday
2 Best Biotech Buyout Plays
Atara Biotherapeutics and Crispr Therapeutics stand out as strong takeover candidates. Here's why.
- Zacks•2 days ago
What's in Store for Bayer (BAYRY) This Earnings Season?
Bayer (BAYRY) is expected to provide pipeline updates along with its first-quarter results.
- Zacks•2 days ago
Will Bristol-Myers (BMY) Disappoint This Earnings Season?
Performance of Opdivo and the impending acquisition of Celgene Corporation will be key areas of focus for the investors, when Bristol-Myers (BMY) reports first-quarter results.
- American City Business Journals•5 days ago
GSK cutting employees at its R&D unit in Collegeville
The changes are part of a new approach to R&D; prioritizing innovation and moving towards delivering a pipeline of medicines with a focus on immunology.
- Zacks•6 days ago
Clovis Focuses on Rubraca Label Expansion, Competition Stiff
Although sales of Clovis' (CLVS) Rubraca improved in the fourth quarter of 2018, the drug may face significant competition going forward. Clovis is also evaluating Rubrca for other cancer indications.
- American City Business Journals•7 days ago
COPD space about to have another drug — this time from a Morrisville concern
A recent FDA approval has one Triangle pharmaceutical company going head to head with the likes Pharma giants such as GSK – in an multi-billion dollar industry company officials believe they have the edge in.
- Zacks•7 days ago
Emergent's (EBS) Chikungunya Vaccine Positive in Phase II Study
Emergent (EBS) posts interim data from the phase II study on its chikungunya vaccine, CHIKV-VLP. The candidate generates positive immune response against the chikungunya virus.
- Zacks•8 days ago
Axsome's AXS-05 Meets Goal in Phase II Study, Shares Up
Axsome's (AXSM) mid-stage candidate, AXS-05, achieves the primary endpoint in a phase II study as a smoking cessation treatment. Shares rise.
- Zacks•8 days ago
Novartis' (NVS) BLA for Ophthalmology Drug Accepted by FDA
The FDA accepts Novartis' (NVS) BLA seeking approval for brolucizumab for the treatment of wet AMD.
- Zacks•9 days ago
Clovis Stalls Mid-Stage Rubraca Study for Bladder Cancer
Clovis Oncology (CLVS) halts mid-stage bladder cancer study evaluating Rubraca monotherapy. It is unlikely to provide meaningful clinical benefit as reviewed by an independent data monitoring committee.
- Reuters•10 days ago
London's FTSE 100 tugged down by miners; IWG lifts midcaps
(Reuters) - Britain's main index lost ground on Monday as miners and oil majors fell, more than offsetting gains in bank stocks. The FTSE 100 was 0.2 percent lower, lagging its European and Asian counterparts, ...
- Investopedia•10 days ago
Top 5 Dividend Stocks in the FTSE for 2018
The FTSE 100 is an index that includes the top 100 companies from the London Stock Exchange. They are ranked by their market capitalization. However, market cap may not be an investor’s only interest in a stock.
- Zacks•12 days ago
Merck's Keytruda Gets FDA Nod for Expanded Lung Cancer Group
Merck (MRK) gets FDA approval to include overall survival data from the KEYNOTE-042 study on Keytruda's label.
- Zacks•12 days ago
Pharma Stock Roundup: AZN, MRK, GSK Get Regulatory Approvals, Sandoz Inks New Deal
Glaxo (GSK) gets FDA approval for a new HIV medicine, Dovato. AstraZeneca (AZN)/Merck's (MRK) Lynparza gets approval in EU for metastatic breast cancer.
- Zacks•13 days ago
Novartis to Market Rizmoic Through Sandoz, Spins Off Alcon
Novartis' (NVS) Sandoz signs an agreement with Japanese company, Shionogi, to commercialize constipation drug in key European markets.
- Zacks•14 days ago
AstraZeneca/Merck's Lynparza Wins EU Nod for Breast Cancer
AstraZeneca (AZN) and Merck gain an EU approval for Lynparza as a monotherapy for treating HER2-negative locally-advanced/metastatic breast cancer.
- Barrons.com•15 days ago
Don’t Give Up on Gilead Stock After GlaxoSmithKline Beat It to a New HIV Drug, Analyst Says
Gilead Sciences stock has long been a leader in the HIV space, so even though stock is off after a competing treatment’s approval, RBC Capital Markets doesn’t think investors should give up just yet.
- Zacks•15 days ago
Emergent's (EBS) Strong Vaccine Portfolio to Fuel Growth
Emergent's (EBS) vaccine portfolio looks promising. The company's recent acquisitions also bode well for growth.
